Biogen Inc. (VIE:BIIB)

Austria · Delayed Price · Currency is EUR

155.85

-0.30 (-0.19%)

Last updated: Dec 4, 2025, 3:30 PM CET

Revenue

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	2011 - 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2011 - 2020
Multiple Sclerosis Product Revenue	4.19B	4.35B	Log In	Log In	Log In	Upgrade
Rare Disease Product Revenue	2.17B	1.99B	Log In	Log In	Log In	Upgrade
Biosimilars Product Revenue	760.80M	793.10M	Log In	Log In	Log In	Upgrade
Other Product Revenue	157.10M	82.50M	Log In	Log In	Log In	Upgrade
Revenue (Other)	2.78B	2.46B	Log In	Log In	Log In	Upgrade
Revenue (Total)	10.07B	9.68B	Log In	Log In	Log In	Upgrade

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	2011 - 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2011 - 2020
United States Revenue	3.46B	3.24B	Log In	Log In	Log In	Upgrade
Rest of World Revenue	3.82B	3.98B	Log In	Log In	Log In	Upgrade
Revenue (Other)	2.78B	2.46B	Log In	Log In	Log In	Upgrade
Revenue (Total)	10.07B	9.68B	Log In	Log In	Log In	Upgrade

Updated Sep 30, 2025. Data Source: Fiscal.ai.